Switzerland· 61532002
Benlysta
A belimumab product containing belimumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Belimumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG04 (belimumab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Belimumab · ATC L04AG04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belimumab costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- Switzerland: $45.43 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Belimumab · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$45.43
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- belimumabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L04AG04
- ATC class
- Belimumab
- Defined daily dose
- 25 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806153200261 StkCHF 583.75
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
61 interactions on record for belimumab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Belimumab · interactions on record
61 records
- 28 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Belimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBenlystaGlaxoSmithKline (Ireland) Limited
- CzechiaBENLYSTAGlaxoSmithKline (Ireland) Limited, Dublin
- United StatesBENLYSTAGlaxoSmithKline LLC
- BelgiumBenlysta 120 mgGlaxoSmithKline
- IcelandBenlystaGlaxoSmithKline (Ireland) Limited
- Japanベリムマブ(遺伝子組換え)グラクソ・スミスクライン
- NetherlandsBenlysta 120 mg, Poeder voor oplossing voor infusieGlaxoSmithKline (Ireland) Ltd.
- SwedenBenlysta 120 mg Pulver till koncentrat till infusionsvätska, lösningGlaxoSmithKline (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Benlysta
- Liechtenstein · Benlysta
- Norway · Benlysta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/54f2fe63-edf1-40a6-9789-332e294c0587 GET /v1/drugs/54f2fe63-edf1-40a6-9789-332e294c0587?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "belimumabum 400 mg",
"valid_from": "2015-05-01",
"limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nDie Wirksamkeit / Zweckmässigkeit von BENLYSTA muss spätestens nach 6 Monaten durch den aktuell behandelnden Arzt zu Händen des Vertrauensarztes reevaluiert werden.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-12-01\",\"validTo\":null},{\"description\":\"<b>Systemischer Lupus erythematodes (SLE)</b><br>\\nErstverordnung durch FachärztInnen für klinische Immunologie und Rheumatologie. Zur Behandlung von erwachsenen Patienten mit aktivem, Autoantikörper-positivem systemischem Lupus erythematodes SLE, die trotz Basistherapie eine hohe Krankheitsaktivität aufweisen (z.B. positiver Test auf anti-dsDNA-Antikörper und niedriges Komplement (C3 und C4)).<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-12-01\",\"validTo\":null},{\"description\":\"<b>Lupusnephritis (LN)</b><br>\\nErstverordnung durch FachärztInnen für klinische Immunologie, Nephrologie und Rheumatologie, welche Erfahrung in der Behandlung einer Lupusnephritis haben. Zur Behandlung von erwachsenen Patienten mit nachgewiesener, aktiver Lupusnephritis (LN) der Klasse III oder IV +/- V, die eine Standardtherapie (entsprechend der Zulassungsstudie) erhalten.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-12-01\",\"validTo\":null}]",
"galenic_form": "Trockensub 400 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2015-05-01",
"self_retention_pct": 10
}See everything about belimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.